ID
41354
Description
Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form has to be filled in during the Treatment period after Circuit Prime is administered and whenever a Bolus of Argatroban is administered. Continuous infusions are recorded in a separate form.
Link
https://clinicaltrials.gov/ct2/show/NCT00039858
Keywords
Versions (1)
- 9/3/20 9/3/20 -
Copyright Holder
GlaxoSmithKline
Uploaded on
September 3, 2020
DOI
To request one please log in.
License
Creative Commons BY-NC 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858
Dosing Information - Circuit Prime and Bolus
- StudyEvent: ODM
Description
Dosing Information - Circuit Prime
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C1533716
- UMLS CUI-3
- C3805286
Description
*Protocol violation
Data type
text
Alias
- UMLS CUI [1]
- C3805286
Description
Part to be filled in: μg **Recommend 50μg/750mL
Data type
integer
Measurement units
- μg
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C3805286
Description
Part to be filled in: mL **Recommend 50μg/750mL
Data type
integer
Measurement units
- mL
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C3805286
Description
Dosing Information - Bolus
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C1533716
- UMLS CUI-3
- C1511237
Description
Number of bolus administered
Data type
text
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C2348184
Description
Please fill in for all nine bolus numbers.
Data type
text
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1521801
Description
Bolus dose
Data type
integer
Measurement units
- mcg/kg
Alias
- UMLS CUI [1]
- C1511237
Description
(dd-mmm-yyyy)
Data type
date
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C0808070
Description
(0000-2359)
Data type
time
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1301880
Description
(0000-2359)
Data type
time
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1522314
Similar models
Dosing Information - Circuit Prime and Bolus
- StudyEvent: ODM
C0019994 (UMLS CUI [1,2])
C2348184 (UMLS CUI [1,2])
C1533716 (UMLS CUI-2)
C3805286 (UMLS CUI-3)
C0304229 (UMLS CUI [1,2])
C3805286 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,2])
C3805286 (UMLS CUI [1,3])
C1533716 (UMLS CUI-2)
C1511237 (UMLS CUI-3)
C2348184 (UMLS CUI [1,2])
C1521801 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,2])
C1522314 (UMLS CUI [1,2])
No comments